Enlivex Therapeutics LtdNASDAQ:ENLV
- LAST PRICE1.4000
- TODAY'S CHANGE (%)-0.0200 (-1.4085%)
- Bid / Lots1.3500/ 3
- Ask / Lots1.8900/ 7
- Open / Previous Close1.4000 / 1.4200
- Day Range
- 52 Week Range
- Volume15,708
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ENLV |
|---|---|---|
| 09:32 ET | 139 | 1.4 |
| 09:34 ET | 2000 | 1.42 |
| 09:45 ET | 1907 | 1.4 |
| 10:01 ET | 1200 | 1.4 |
| 10:46 ET | 335 | 1.415 |
| 11:29 ET | 100 | 1.4038 |
| 11:33 ET | 1550 | 1.4 |
| 11:49 ET | 987 | 1.4009 |
| 12:05 ET | 1400 | 1.39 |
| 12:07 ET | 294 | 1.39 |
| 12:34 ET | 200 | 1.395 |
| 12:39 ET | 730 | 1.4 |
| 02:13 ET | 140 | 1.415 |
| 03:20 ET | 1500 | 1.4254 |
| 03:38 ET | 112 | 1.41 |
| 03:48 ET | 100 | 1.41 |
| 03:59 ET | 462 | 1.4 |
Apr 29, 2024
Enlivex CEO Issues Letter to Shareholders -- Perspectives on Recent Events, from 8:00AM ET on Monday Apr 29, 2024 by Dow Jones
8:00AM ET on Monday Apr 29, 2024 by Dow Jones
Apr 23, 2024
DJ Enlivex Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co., from 6:43AM ET on Tuesday Apr 23, 2024 by Dow Jones
6:43AM ET on Tuesday Apr 23, 2024 by Dow Jones
Apr 22, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Enlivex Therapeutics Ltd | 26.7M | -0.9x | --- |
UNITY Biotechnology Inc | 25.7M | -0.6x | --- |
Biora Therapeutics Inc | 25.7M | -0.1x | --- |
NKGen Biotech Inc | 25.6M | -0.3x | --- |
Iterum Therapeutics PLC | 24.7M | -0.6x | --- |
Eom Pharmaceutical Holdings Inc | 23.8M | -4.8x | --- |
Company Information
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Contact Information
- Headquarters
- 14 Einstein St.NESS-ZIONA, Israel 7403618
- Phone
- ---
- Fax
- ---
Executives
- Chief Executive Officer
- Oren Hershkovitz
- Executive Chairman of the Board
- Shai Novik
- Founder, Chief Scientific Officer and Medical Officer
- Dror Mevorach
- Chief Financial Officer
- Shachar Shlosberger
- Director
- Baruch Halpert
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $26.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 18.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-1.56 |
Book Value | $1.62 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
